StockNews.com Downgrades Simulations Plus (NASDAQ:SLP) to Sell

Simulations Plus (NASDAQ:SLP) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Monday.

SLP has been the subject of a number of other reports. William Blair reissued an “outperform” rating on shares of Simulations Plus in a research note on Thursday, October 24th. KeyCorp started coverage on Simulations Plus in a research report on Monday, July 29th. They set an “overweight” rating and a $47.00 price target on the stock. JMP Securities began coverage on Simulations Plus in a report on Tuesday, July 16th. They issued a “market perform” rating for the company. Finally, BTIG Research dropped their target price on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $54.50.

Simulations Plus Price Performance

NASDAQ SLP opened at $28.60 on Monday. The business’s 50-day moving average is $31.93 and its 200 day moving average is $39.66. The stock has a market capitalization of $574.00 million, a PE ratio of 58.37 and a beta of 0.71. Simulations Plus has a 1 year low of $27.22 and a 1 year high of $51.22.

Simulations Plus (NASDAQ:SLP) last posted its earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The firm had revenue of $18.70 million for the quarter, compared to analysts’ expectations of $19.73 million. During the same period in the previous year, the firm earned $0.18 earnings per share. The business’s revenue was up 19.9% compared to the same quarter last year. As a group, equities research analysts anticipate that Simulations Plus will post 1.11 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $27.66, for a total transaction of $553,200.00. Following the sale, the director now directly owns 3,462,584 shares of the company’s stock, valued at approximately $95,775,073.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders have sold 60,750 shares of company stock valued at $1,905,655. 20.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC purchased a new position in shares of Simulations Plus in the 1st quarter worth $70,000. BNP Paribas Financial Markets boosted its holdings in shares of Simulations Plus by 9.1% in the first quarter. BNP Paribas Financial Markets now owns 14,143 shares of the technology company’s stock worth $582,000 after buying an additional 1,174 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in Simulations Plus during the first quarter valued at approximately $208,000. Vanguard Group Inc. raised its position in Simulations Plus by 1.1% in the first quarter. Vanguard Group Inc. now owns 1,135,105 shares of the technology company’s stock worth $46,710,000 after acquiring an additional 12,636 shares during the period. Finally, EntryPoint Capital LLC purchased a new position in shares of Simulations Plus during the 1st quarter worth $57,000. 78.08% of the stock is owned by institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.